Merus N.V. logo

Merus N.V. (2GH)

Market Closed
9 Jul, 20:00
46. 40
-0.8
-1.69%
2.31B Market Cap
- P/E Ratio
0% Div Yield
0 Volume
-2.67 Eps
47.2
Previous Close
Day Range
46.4 47.2
Year Range
30.2 56
Want to track 2GH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 17 days

Summary

2GH closed Wednesday higher at €46.6, an increase of 4.95% from Tuesday's close, completing a monthly increase of 4.48% or €2. Over the past 12 months, 2GH stock gained 15.35%.
2GH is not paying dividends to its shareholders.
The last earnings report, released on May 06, 2025, missed the consensus estimates by -0.34%. On average, the company has fell short of earnings expectations by -0.17%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

2GH Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

Zacks | 2 days ago
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

Merus N.V. (MRUS) came out with a quarterly loss of $1.40 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $0.59 per share a year ago.

Zacks | 2 months ago
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 2 months ago

Merus N.V. Dividends

2GH is not paying dividends to its shareholders.

Merus N.V. Earnings

7 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
2GH is not paying dividends to its shareholders.
7 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
6 May 2025 Date
-
Cons. EPS
-
EPS
26 Feb 2025 Date
-
Cons. EPS
-
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS

Merus N.V. (2GH) FAQ

What is the stock price today?

The current price is €46.60.

On which exchange is it traded?

Merus N.V. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is 2GH.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 2.31B.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Merus N.V. ever had a stock split?

No, there has never been a stock split.

Merus N.V. Profile

Biotechnology Industry
Healthcare Sector
Sven Ante Lundberg CEO
XBER Exchange
NL0011606264 ISIN
NL Country
260 Employees
- Last Dividend
- Last Split
19 May 2016 IPO Date

Overview

Merus N.V. is positioned at the forefront of immuno-oncology, dedicated to pioneering the development of innovative antibody therapeutics. Established in 2003 and based in Utrecht, the Netherlands, Merus is focused on advancing a portfolio of bispecific and trispecific antibody candidates through clinical trials. These revolutionary treatments are being explored for their potential in addressing a wide array of cancers, including metastatic breast cancer, castration-resistant prostate cancer, non-small cell lung cancer, and relapsed/refractory T cell lymphoma, among others. The company's approach is distinguished by collaborations with leading pharmaceutical entities such as Betta Pharmaceuticals, Incyte Corporation, and Gilead Sciences, Inc., aiming to harness the power of cutting-edge science in the fight against cancer.

Products and Services

  • Zenocutuzumab (MCLA-128)

    This bispecific antibody candidate is being investigated in phase 2 clinical trials for metastatic breast cancer and castration-resistant prostate cancer. Additionally, it is part of Phase 1/2 trials targeting solid tumors with Neuregulin 1. Its development showcases Merus N.V.'s commitment to addressing complex cancers with innovative therapeutic options.

  • MCLA-158

    Currently in phase I clinical trials, MCLA-158 is designed to target solid tumors. This bispecific antibody leverages a novel approach to bind to cancer cells, highlighting Merus's dedication to expanding its cancer treatment portfolio.

  • MCLA-145

    In phase 1 clinical trials, MCLA-145 represents a key part of Merus's pipeline. Developed in collaboration with Incyte Corporation, this product is exploring potential treatments for patients with solid tumors, underlining the company's strategy of partnership in innovation.

  • MCLA-129

    This candidate is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors. MCLA-129 is also being developed under a collaboration agreement with Betta Pharmaceuticals, showcasing Merus's collaborative approach towards accelerating the development of cancer therapies.

  • ONO-4685

    ONO-4685 is in a Phase 1 clinical trial aimed at treating patients with relapsed/refractory T cell lymphoma. This reflects Merus N.V.'s efforts to explore treatments for a broader range of cancers, including those with limited treatment options.

  • Novel Antibody-based Trispecific T-cell Engagers

    In partnership with Gilead Sciences, Inc., Merus is working on the discovery of trispecific T-cell engagers. This initiative illustrates the company's pioneering spirit in leveraging antibody technology to potentially revolutionize cancer immunotherapy.

Contact Information

Address: Yalelaan 62
Phone: 31 30 253 8800